Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

U.S. Seeks to Develop Late-Stage Smallpox Antivirals

by Global Biodefense Staff
February 14, 2018
Biomedical Advanced Research and Development Authority

The etiological agent responsible for smallpox disease, Variola viridae (VARV) is responsible for the deaths of hundreds of millions of people throughout history.

While smallpox disease is eradicated, repositories of VARV remain, and it is still considered one of the most dangerous human pathogens as it is highly communicable and carries exceptionally high morbidity.

While there is a licensed smallpox vaccine stockpiled for the pre-exposure prophylaxis against smallpox, there are currently no approved therapeutic antivirals for the treatment of symptomatic smallpox. The Biomedical Advanced Research and Development Authority (BARDA) is seeking to procure smallpox therapeutic antiviral agents for the Strategic National Stockpile that can be used in the event of an outbreak to treat symptomatic patients.

It is anticipated that a formal Request for Proposals may be available electronically through the FedBizOpps website sometime in February 2018 for 45 days with proposals being due in April 2018. One contract award with both cost reimbursement and firm-fixed CLINs will be awarded by July 2018. The anticipated base period of performance for any resultant contract(s) will be for a total of 60 months and up to 10 years with options if exercised.

All proposals submitted to any future solicitations shall have evidence of two formulations of the antiviral (parenteral and nonparenteral), an active FDA IND or licensed product with completed phase I trials for both products, evidence of efficacy in at least two animal models accepted by the FDA for the evaluation of a smallpox medical countermeasure, and the ability of the Offeror to deliver at least one formulation to the Strategic National Stockpile upon contract award (e.g. FDA approval, pre-EUA IND on file).

Additional details and requirements will be described in the forthcoming solicitation.

Source: FBO.gov Solicitation Number: 18-100-SOL-00011

Tags: AntiviralsASPRBARDABioterrorismHHSPoxvirusesRequest for ProposalsSelect AgentsSmallpoxStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC